5-Methyldeoxycytidine

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 5-Methyldeoxycytidine
• 英文别名: 4-amino-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidin-2-one
• 化学式: C₁₀H₁₅N₃O₄
• 分子量: 241.24
• InChiKey: LUCHPKXVUGJYGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
  申请人：Translate Bio MA, Inc.

  公开号：EP3533873A1

  公开（公告）日：2019-09-04

  The disclosure provides multimeric oligonucleotide compounds, comprising two or more target-specific oligonucleotides (e.g., antisense oligonucleotides (ASOs)), each being resistant to cleavage, and linked together by a cleavable linker. In particular, two or more linked target-specific oligonucleotides, each to a different target, allows concomitant inhibition of multiple genes' expression levels, while exhibiting favorable pharmacokinetic and pharmacodynamic properties. Methods of making and uses of the described compounds are also provided

  本公开提供了多聚物寡核苷酸化合物，包括两个或多个靶向特异性寡核苷酸（如反义寡核苷酸（ASO）），每个寡核苷酸都具有抗裂解性，并通过可裂解连接体连接在一起。特别是两个或更多链接的靶标特异性寡核苷酸，每个都针对不同的靶标，可以同时抑制多个基因的表达水平，同时表现出良好的药代动力学和药效学特性。还提供了所述化合物的制造方法和用途
• TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES
  申请人：Nuevolution A/S

  公开号：EP1402024B1

  公开（公告）日：2007-08-22
• [EN] TREATMENT OF FATTY LIVER DISEASE<br/>[FR] TRAITEMENT DE LA STÉATOSE HÉPATIQUE
  申请人：AVOGADRO DEV CORP

  公开号：WO2020146477A1

  公开（公告）日：2020-07-16

  The present invention relates to a method of treating fatty liver disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) 5'-N1N2N3N4N5N6-N7N8-dCm-dGc-N11N12N13N14N15N16-N17N18-3'. The fatty liver disease can be non-alcoholic fatty liver disease, such as simple fatty liver disease or NASH. The invention also relates to the use of adiponectin as a biomarker for identifying subjects more likely to respond to treatment with the compound on Formula (I) 5'-N1N2N3N4N5N6-N7N8-dCm-dGc-N11N12N13N14N15N16-N17N18-3' and for assessing response of the subject during treatment with the compound of Formula (I) 5'-N1N2N3N4N5N6-N7N8-dCm-dGc-N11N12N13N14N15N16-N17N18-3'.